Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Lexicon, Alimera, and Akebia are the top stories to watch in the biotech sector this Monday morning.
The S&P 500 breaks a three-day losing streak as AK Steel, Idenix Pharmaceuticals, and Alimera Sciences all rocket higher by double-digits.
No podcast episodes available.
ALIM earnings call for the period ending September 30, 2021.
ALIM earnings call for the period ending June 30, 2021.
ALIM earnings call for the period ending March 31, 2021.
ALIM earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.